Net Sales

+367% (from $2,607,013 to $12,181,971)

A dramatic surge in net sales is evident in Q4 2024, likely driven by a combination of heightened demand for higher‐margin product lines and expanded market penetration compared to Q4 2023, where sales were limited due to earlier operational constraints. This strong improvement builds on the previous period’s lower figures and suggests successful strategic initiatives that accelerated revenue growth. " "

Operating Income

+361% (from $791,266 to $3,646,789)

Operating income nearly quadrupled as improved sales mix and cost efficiencies—such as higher contributions from cosmetic ingredients and tighter operating expense management—helped overcome the comparatively low performance of Q4 2023. The positive effect of a stronger gross margin in the current period contrasts with the previous period’s constrained margins. " "

Net Income

+341% (from $737,439 to $3,250,875)

Net income surged significantly due to much higher operating profits combined with improved other income elements, reflecting the compounding benefits of previous net sales and operating income gains. The jump in net income from Q4 2023 highlights the recovery in profitability that had been subdued in the earlier period. " "

Earnings per Share

+344% (from $0.16 to $0.71)

EPS improved dramatically in Q4 2024 as a direct result of the amplified net income as well as the underlying increases in sales and operating performance. The substantial uplift in EPS from the modest levels seen in Q4 2023 demonstrates the impact of higher profitability on the per share value. " "

Operating Cash Flow

−76% (from $1,127,570 to $269,297)

Operating cash flow dropped sharply despite higher operating income, largely due to adverse working capital movements and significant cash used in investing activities. The lower cash flow in Q4 2024 relative to Q4 2023 suggests that while profitability improved, liquidity was affected by timing differences in receivables, payables, and investment reallocation. " "

Total Assets

+6.7% (from $12,922,838 to $13,797,335)

A moderate increase in total assets was recorded, primarily due to reinvestments in marketable securities offsetting decreases in cash and cash equivalents. This overall asset growth builds on the previous period’s balance sheet position by reflecting strategic asset reallocation rather than organic cash accumulation. " "

Total Liabilities

+24.5% (from $1,534,256 to $1,914,469)

Total liabilities grew noticeably in Q4 2024, driven mainly by a significant rise in accounts payable. This increase indicates higher short-term obligations relative to Q4 2023 and may reflect elevated operational activity and supplier commitments that have grown alongside revenue. " "

Revenue (Geographical)

5% decline (from $2.61M to $2.48M combined)

Geographical revenue declined slightly as U.S. sales increased (by $215,019 or 10%) while direct sales in other countries fell by $212,424 (26%). This shift suggests that although domestic sales improved—partly driven by higher cosmetic ingredient orders—the decline in international sales (affected by market adjustments such as reformulations and overstocking corrections) led to an overall marginal contraction. " " "